老年慢性乙型肝炎患者用药治疗后乙肝病毒耐药基因多位点变异
发布时间：2018-08-14 15:29
【摘要】：目的分析拉米夫定(LAM)和恩替卡韦(ECV)联合用药及单独用LAM后老年乙肝患者乙肝病毒(HBV)耐药基因突变位点及与基因型的关系。方法选择治疗前未检测出HBV-YMDD变异的老年乙肝患者100例,随机分为两组,在患者治疗后24个月检测基因分型和反转录酶(RT)区位点变异。结果联合用药组中检出耐药突变类型分别为rt T184L+L180M+M204V、rt T184L+S202G+L180M+M204V、rt M250L+M204I;单用药组检出耐药基因突变类型分别为rt L180M+M204V、rt L180M+M204I、rt M204I。结论初期使用LAM联合ECV治疗老年乙肝患者24个月后耐药突变率仅为6%;联合用药在B和C两种基因型中的耐药检出率没有明显不同。
[Abstract]:Objective to analyze the relationship between HBV (HBV) resistance gene mutation sites and genotypes in elderly patients with hepatitis B after lamivudine (LAM) and entecavir (ECV) combined with LAM alone. Methods 100 elderly patients with hepatitis B without HBV-YMDD mutation were randomly divided into two groups. Genotyping and reverse transcriptase (RT) site variation were detected 24 months after treatment. Results the mutation types of drug resistance were RT T184L L180M M204V rt T184L S2020G L180M M204VtM250L M204I in combination group and RT L180M M204Vrt M204I204I in single drug group. Conclusion the mutation rate of drug resistance in elderly patients with hepatitis B treated with LAM combined with ECV at the beginning of 24 months was only 60.There was no significant difference in the detection rate of drug resistance between B and C genotypes.
【作者单位】： 河北医科大学第一医院检验科;河北医科大学第四医院检验科;
【基金】：河北省卫生厅科研立项(20130565)
【分类号】：R440;R512.62
本文编号：2183306
[Abstract]:Objective to analyze the relationship between HBV (HBV) resistance gene mutation sites and genotypes in elderly patients with hepatitis B after lamivudine (LAM) and entecavir (ECV) combined with LAM alone. Methods 100 elderly patients with hepatitis B without HBV-YMDD mutation were randomly divided into two groups. Genotyping and reverse transcriptase (RT) site variation were detected 24 months after treatment. Results the mutation types of drug resistance were RT T184L L180M M204V rt T184L S2020G L180M M204VtM250L M204I in combination group and RT L180M M204Vrt M204I204I in single drug group. Conclusion the mutation rate of drug resistance in elderly patients with hepatitis B treated with LAM combined with ECV at the beginning of 24 months was only 60.There was no significant difference in the detection rate of drug resistance between B and C genotypes.
【作者单位】： 河北医科大学第一医院检验科;河北医科大学第四医院检验科;
【基金】：河北省卫生厅科研立项(20130565)
【分类号】：R440;R512.62
【相似文献】
相关期刊论文 前3条
1 杨永林;孙启俊;马贵明;黄祖瑚;;献血者HBsAg多位点变异1例[J];中国输血杂志;2007年05期
2 姜斌;宗成国;蒋雪芹;尹家俊;;乙肝病毒前C基因区1896位点变异的实验研究[J];中国实验诊断学;2009年03期
3 ;[J];;年期
，本文编号：2183306
本文链接：https://www.wllwen.com/yixuelunwen/chuanranbingxuelunwen/2183306.html
最近更新
教材专著
